The planned restructuring is part of a global restructuring. In Ghent, the company has announced its intention to cut 67 jobs, while 32 jobs are threatened at the head office in Diegem. Sanofi employs around 1,600 people in Belgium.
The company says it must adapt its way of working and further modernize its organization “to become a global player in immunology”. The focus will be on new vaccines and drugs in immunology that can be “first or best in class and make a real difference to the patient”.
“We currently have twelve new medicines and vaccines in clinical development that could become promising new treatments for immune-related diseases,” the company said. As a result, a number of early-stage research activities in Ghent will be stopped.
Sanofi says it is looking at all possible solutions for employees whose positions may be affected.
